Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Abstract Trastuzumab is used to treat HER2-amplified metastatic gastric cancer; however, most patients become trastuzumab-resistant within a year. Knowledge of the mechanisms underlying trastuzumab resistance is required to overcome this limitation. Here, we aimed to elucidate this resistance mechan...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Nature Portfolio
2023-12-01
|
| Serija: | Scientific Reports |
| Online dostop: | https://doi.org/10.1038/s41598-023-49646-5 |